These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 15320727)

  • 1. The design and synthesis of aryl hydroxamic acid inhibitors of MMPs and TACE.
    Levin JI
    Curr Top Med Chem; 2004; 4(12):1289-310. PubMed ID: 15320727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design strategies for the identification of MMP-13 and Tace inhibitors.
    Skotnicki JS; DiGrandi MJ; Levin JI
    Curr Opin Drug Discov Devel; 2003 Sep; 6(5):742-59. PubMed ID: 14579524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.
    Zask A; Gu Y; Albright JD; Du X; Hogan M; Levin JI; Chen JM; Killar LM; Sung A; DiJoseph JF; Sharr MA; Roth CE; Skala S; Jin G; Cowling R; Mohler KM; Barone D; Black R; March C; Skotnicki JS
    Bioorg Med Chem Lett; 2003 Apr; 13(8):1487-90. PubMed ID: 12668018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.
    Nuti E; Casalini F; Avramova SI; Santamaria S; Cercignani G; Marinelli L; La Pietra V; Novellino E; Orlandini E; Nencetti S; Tuccinardi T; Martinelli A; Lim NH; Visse R; Nagase H; Rossello A
    J Med Chem; 2009 Aug; 52(15):4757-73. PubMed ID: 19606871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sulfonate ester hydroxamic acids as potent and selective inhibitors of TACE enzyme.
    Levin JI; Du MT
    Drug Des Discov; 2003; 18(4):123-6. PubMed ID: 15553924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta-aryl-succinic acid hydroxamates as dual inhibitors of matrix metalloproteinases and tumor necrosis factor alpha converting enzyme.
    Kottirsch G; Koch G; Feifel R; Neumann U
    J Med Chem; 2002 May; 45(11):2289-93. PubMed ID: 12014967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation.
    Chun K; Park SK; Kim HM; Choi Y; Kim MH; Park CH; Joe BY; Chun TG; Choi HM; Lee HY; Hong SH; Kim MS; Nam KY; Han G
    Bioorg Med Chem; 2008 Jan; 16(1):530-5. PubMed ID: 17936631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.
    Duan JJ; Chen L; Wasserman ZR; Lu Z; Liu RQ; Covington MB; Qian M; Hardman KD; Magolda RL; Newton RC; Christ DD; Wexler RR; Decicco CP
    J Med Chem; 2002 Nov; 45(23):4954-7. PubMed ID: 12408705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benzodiazepine inhibitors of the MMPs and TACE.
    Nelson FC; Delos Santos E; Levin JI; Chen JM; Skotnicki JS; DiJoseph JF; Sharr MA; Sung A; Killar LM; Cowling R; Jin G; Roth CE; Albright JD
    Bioorg Med Chem Lett; 2002 Oct; 12(20):2867-70. PubMed ID: 12270165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.
    Aranapakam V; Grosu GT; Davis JM; Hu B; Ellingboe J; Baker JL; Skotnicki JS; Zask A; DiJoseph JF; Sung A; Sharr MA; Killar LM; Walter T; Jin G; Cowling R
    J Med Chem; 2003 Jun; 46(12):2361-75. PubMed ID: 12773041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release.
    Xue CB; He X; Corbett RL; Roderick J; Wasserman ZR; Liu RQ; Jaffee BD; Covington MB; Qian M; Trzaskos JM; Newton RC; Magolda RL; Wexler RR; Decicco CP
    J Med Chem; 2001 Oct; 44(21):3351-4. PubMed ID: 11585440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme.
    Duan JJ; Lu Z; Wasserman ZR; Liu RQ; Covington MB; Decicco CP
    Bioorg Med Chem Lett; 2005 Jun; 15(12):2970-3. PubMed ID: 15908214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.
    Aranapakam V; Davis JM; Grosu GT; Baker J; Ellingboe J; Zask A; Levin JI; Sandanayaka VP; Du M; Skotnicki JS; DiJoseph JF; Sung A; Sharr MA; Killar LM; Walter T; Jin G; Cowling R; Tillett J; Zhao W; McDevitt J; Xu ZB
    J Med Chem; 2003 Jun; 46(12):2376-96. PubMed ID: 12773042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The application of x-ray, NMR, and molecular modeling in the design of MMP inhibitors.
    Rush TS; Powers R
    Curr Top Med Chem; 2004; 4(12):1311-27. PubMed ID: 15320728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of selective hydroxamic acid inhibitors of tumor necrosis factor-alpha converting enzyme.
    Holms J; Mast K; Marcotte P; Elmore I; Li J; Pease L; Glaser K; Morgan D; Michaelides M; Davidsen S
    Bioorg Med Chem Lett; 2001 Nov; 11(22):2907-10. PubMed ID: 11677124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Azasugar-based MMP/ADAM inhibitors as antipsoriatic agents.
    Moriyama H; Tsukida T; Inoue Y; Yokota K; Yoshino K; Kondo H; Miura N; Nishimura S
    J Med Chem; 2004 Apr; 47(8):1930-8. PubMed ID: 15055993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors.
    Hanessian S; Bouzbouz S; Boudon A; Tucker GC; Peyroulan D
    Bioorg Med Chem Lett; 1999 Jun; 9(12):1691-6. PubMed ID: 10397503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New alpha-substituted succinate-based hydroxamic acids as TNFalpha convertase inhibitors.
    Barlaam B; Bird TG; Lambert-Van Der Brempt C; Campbell D; Foster SJ; Maciewicz R
    J Med Chem; 1999 Nov; 42(23):4890-908. PubMed ID: 10579851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and evaluation of novel azasugar-based MMP/ADAM inhibitors.
    Moriyama H; Tsukida T; Inoue Y; Kondo H; Yoshino K; Nishimura S
    Bioorg Med Chem Lett; 2003 Aug; 13(16):2741-4. PubMed ID: 12873505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conversion of potent MMP inhibitors into selective TACE inhibitors.
    Cherney RJ; King BW; Gilmore JL; Liu RQ; Covington MB; Duan JJ; Decicco CP
    Bioorg Med Chem Lett; 2006 Feb; 16(4):1028-31. PubMed ID: 16289878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.